Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alstrm syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Rhythm Pharmaceuticals, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

-- -18.8% PLACEBO-ADJUSTED DIFFERENCE IN BMI REDUCTION ACHIEVED IN ALL PATIENTS (N=142) AT 52 WEEKS, INCLUDING 12 JAPANESE PATIENTS AND 10 SUPPLEMENTAL PATIENTS WITH ACQUIRED HYPOTHALAMIC OBESITY -- --MARCH 20, 2026PDUFA GOAL DATE FOR SNDA FOR SETMELANOTIDE IN ACQUIRED HYPOTHALAMIC OBESITY --

RHYTHM PHARMACEUTICALS ANNOUNCES ADDITIONAL POSITIVE DATA FROM PHASE 3 TRANSCEND TRIAL OF SETMELANOTIDE IN PATIENTS WITH ACQUIRED HYPOTHALAMIC OBESITY

-- FOURTH QUARTER 2025 NET PRODUCT REVENUE FROM GLOBAL SALES OF IMCIVREE  (SETMELANOTIDE) OF $57.3 MILLION -- -- MARCH 20, 2026 PDUFA GOAL DATE FOR SNDA FOR SETMELANOTIDE IN ACQUIRED HYPOTHALAMIC OBESITY (HO) -- -- PHASE 2 OPEN-LABEL EXTENSION DATA SHOWED BIVAMELAGON ACHIEVED PERSISTENT BMI REDUCTIONS AT SIX AND NINE MONTHS; COMPLETED POSITIVE END-OF-PHASE-2 MEETING WITH FDA -- -- ON TRACK TO REPORT TOPLINE DATA FROM 12-PATIENT JAPANESE COHORT OF SETMELANOTIDE PHASE 3 TRIAL IN ACQUIRED HO IN MARCH 2026 -- -- ON TRACK TO REPORT TOPLINE DATA FROM PHASE 3 EMANATE TRIAL EVALUATING SETMELANOTIDE IN RARE GENETICALLY CAUSED MELANOCORTIN-4 RECEPTOR (MC4R) PATHWAY DISEASES IN MARCH 2026 -- -- MANAGEMENT TO HOST CONFERENCE CALL TODAY AT 8:00 A.M. ET -- BOSTON, FEB. 26, 2026 (GLOBE NEWSWIRE) -- RHYTHM PHARMACEUTICALS, INC. (NASDAQ: RYTM), A GLOBAL COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON TRANSFORMING THE LIVES OF PATIENTS LIVING WITH RARE NEUROENDOCRINE DISEASES, TODAY REPORTED FINANCIAL RESULTS AND PROVIDED A BUSINESS UPDATE FOR THE FOURTH QUARTER AND FULL YEAR ENDED DECEMBER 31, 2025.

RHYTHM PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND BUSINESS UPDATE

BOSTON, FEB. 17, 2026 (GLOBE NEWSWIRE) -- RHYTHM PHARMACEUTICALS, INC. (NASDAQ: RYTM), A GLOBAL COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON TRANSFORMING THE LIVES OF PATIENTS LIVING WITH RARE NEUROENDOCRINE DISEASES, TODAY ANNOUNCED THAT IT WILL HOST A LIVE CONFERENCE CALL AND WEBCAST AT 8 A.M. ET ON THURSDAY, FEBRUARY 26, 2026 TO REPORT ITS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE.

RHYTHM PHARMACEUTICALS TO REPORT FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS ON THURSDAY, FEBRUARY 26, 2026

BOSTON, FEB. 05, 2026 (GLOBE NEWSWIRE) -- RHYTHM PHARMACEUTICALS, INC. (NASDAQ: RYTM), A GLOBAL COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON TRANSFORMING THE LIVES OF PATIENTS LIVING WITH RARE NEUROENDOCRINE DISEASES, TODAY ANNOUNCED THAT HUNTER C. SMITH, CHIEF FINANCIAL OFFICER, WILL PARTICIPATE IN A FIRESIDE CHAT AT THE UPCOMING GUGGENHEIM EMERGING OUTLOOK: BIOTECH SUMMIT 2026 CONFERENCE ON WEDNESDAY, FEBRUARY 11 AT 11:00 A.M.

RHYTHM PHARMACEUTICALS ANNOUNCES PARTICIPATION IN UPCOMING GUGGENHEIM BIOTECH SUMMIT

-- Q4 2025 PRELIMINARY NET PRODUCT REVENUES FROM GLOBAL SALES OF IMCIVREE (SETMELANOTIDE) OF APPROXIMATELY $57 MILLION FOR THE FOURTH QUARTER OF 2025, AN 11% INCREASE OVER Q3 2025 -- -- FY 2025 PRELIMINARY NET PRODUCT REVENUE OF APPROXIMATELY $194 MILLION, APPROXIMATELY 50% INCREASE FROM FY2024 -- -- MARCH 20, 2026 PDUFA GOAL DATE FOR SNDA FOR SETMELANOTIDE IN ACQUIRED HYPOTHALAMIC OBESITY -- -- ON TRACK TO REPORT TOPLINE DATA FROM 12-PATIENT JAPANESE COHORT OF SETMELANOTIDE PHASE 3 TRIAL IN ACQUIRED HYPOTHALAMIC OBESITY IN FIRST QUARTER OF 2026 -- -- ON TRACK TO REPORT TOPLINE DATA FROM PHASE 3 EMANATE TRIAL EVALUATING SETMELANOTIDE IN GENETICALLY CAUSED MC4R PATHWAY DISEASES IN FIRST QUARTER OF 2026 -- BOSTON, JAN. 09, 2026 (GLOBE NEWSWIRE) -- RHYTHM PHARMACEUTICALS, INC. (NASDAQ: RYTM), A GLOBAL COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON TRANSFORMING THE LIVES OF PATIENTS LIVING WITH RARE NEUROENDOCRINE DISEASES, TODAY ANNOUNCED PRELIMINARY UNAUDITED NET PRODUCT REVENUES FROM GLOBAL SALES OF IMCIVREE (SETMELANOTIDE) FOR THE FOURTH QUARTER AND FULL YEAR OF 2025 AND UPCOMING MILESTONES. 2025 WAS A YEAR OF STRONG EXECUTION AND REFLECTS SIGNIFICANT PROGRESS TOWARD OUR MISSION OF TRANSFORMING THE LIVES OF PATIENTS WITH RARE NEUROENDOCRINE DISEASES, SAID DAVID MEEKER, M.D.

RHYTHM PHARMACEUTICALS ANNOUNCES PRELIMINARY, UNAUDITED FOURTH QUARTER AND FULL YEAR 2025 NET PRODUCT REVENUES AND UPCOMING MILESTONES

-- BMI AND HYPERPHAGIA REDUCTIONS HAVE BEEN OBSERVED IN PATIENTS WITH PWS TREATED WITH SETMELANOTIDE AT MONTH 3 (N=8) AND MONTH 6 (N=5); 17 OF 18 ENROLLED PATIENTS REMAIN ON THERAPY -- -- PROMISING RESULTS SUPPORTIVE OF PHASE 3, REGISTRATIONAL TRIAL OF SETMELANOTIDE IN PWS --

RHYTHM PHARMACEUTICALS ANNOUNCES PRELIMINARY DATA FROM EXPLORATORY PHASE 2 TRIAL THAT SHOWED SETMELANOTIDE DEMONSTRATED POSITIVE EFFICACY SIGNAL IN PRADER-WILLI SYNDROME

BOSTON, DEC. 10, 2025 (GLOBE NEWSWIRE) -- RHYTHM PHARMACEUTICALS, INC. (NASDAQ: RYTM), A GLOBAL COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON TRANSFORMING THE LIVES OF PATIENTS LIVING WITH RARE NEUROENDOCRINE DISEASES, TODAY ANNOUNCED THAT IT WILL HOST A LIVE CONFERENCE CALL AND WEBCAST ON THURSDAY, DECEMBER 11 AT 8:00 A.M. ET TO DISCLOSE PRELIMINARY DATA FROM ITS EXPLORATORY PHASE 2 TRIAL OF SETMELANOTIDE IN PATIENTS WITH PRADER-WILLI SYNDROME (PWS).

RHYTHM PHARMACEUTICALS TO ANNOUNCE PRELIMINARY DATA FROM EXPLORATORY PHASE 2 TRIAL EVALUATING SETMELANOTIDE IN PRADER-WILLI SYNDROME

PHASE 3 TRANSCEND TRIAL DATA SHOWED SETMELANOTIDE ACHIEVED SIGNIFICANT BMI REDUCTIONS IN PATIENTS WITH ACQUIRED HYPOTHALAMIC OBESITY ON CONCOMITANT TREATMENT WITH GLP-1 THERAPY   ANALYSIS OF DATA FROM PHASE 3 TRANSCEND TRIAL SHOW CLINICALLY MEANINGFUL CHANGES IN CARDIOMETABOLIC PARAMETERS IN PATIENTS WITH ACQUIRED HYPOTHALAMIC OBESITY TREATED WITH SETMELANOTIDE FOR 52 WEEKS  BOSTON, NOV. 10, 2025 (GLOBE NEWSWIRE) -- RHYTHM PHARMACEUTICALS, INC. (NASDAQ: RYTM), A GLOBAL COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON TRANSFORMING THE LIVES OF PATIENTS LIVING WITH RARE NEUROENDOCRINE DISEASES, TODAY ANNOUNCED THAT RHYTHM AND ITS PARTNERS DELIVERED FOUR RHYTHM DATA PRESENTATIONS AT OBESITYWEEK 2025, HELD LAST WEEK IN ATLANTA, GA. ACQUIRED HYPOTHALAMIC OBESITY IS A SEVERE AND COMPLEX DISEASE THAT PROFOUNDLY IMPACTS THE LIVES OF PATIENTS AND FAMILIES, AFFECTING NOT ONLY BODY WEIGHT AND HUNGER, BUT ALSO CAUSING SEVERE IMPLICATIONS FOR DAILY FUNCTIONING, SAID CHRISTIAN ROTH, M.D.

RHYTHM PHARMACEUTICALS ANNOUNCES PRESENTATION OF FOUR DATASETS AT OBESITYWEEK 2025

-- FDA SETS UPDATED PDUFA GOAL DATE OF MARCH 20, 2026  -- COMPANY TO HOLD CONFERENCE TODAY AT 8:00 A.M. -- BOSTON, NOV. 07, 2025 (GLOBE NEWSWIRE) -- RHYTHM PHARMACEUTICALS, INC. (NASDAQ: RYTM), A GLOBAL COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON TRANSFORMING THE LIVES OF PATIENTS LIVING WITH RARE NEUROENDOCRINE DISEASES, TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS EXTENDED BY THREE MONTHS THE REVIEW PERIOD FOR THE SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) FOR IMCIVREE (SETMELANOTIDE) FOR THE TREATMENT OF ACQUIRED HYPOTHALAMIC OBESITY.

RHYTHM PHARMACEUTICALS ANNOUNCES FDA EXTENSION OF REVIEW PERIOD FOR IMCIVREE (SETMELANOTIDE) FOR PATIENTS WITH ACQUIRED HYPOTHALAMIC OBESITY

BOSTON, NOV. 05, 2025 (GLOBE NEWSWIRE) -- RHYTHM PHARMACEUTICALS, INC. (NASDAQ: RYTM), A GLOBAL COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON TRANSFORMING THE LIVES OF PATIENTS LIVING WITH RARE NEUROENDOCRINE DISEASES, TODAY ANNOUNCED THAT IT HAS ENTERED INTO PRODUCT LISTING AGREEMENTS IN THE PROVINCES OF ONTARIO, ALBERTA, BRITISH COLUMBIA, SASKATCHEWAN, NOVA SCOTIA AND WITH THE FEDERAL NON-INSURED HEALTH BENEFITS (NIHB) PROGRAM FOR THE PUBLIC REIMBURSEMENT OF IMCIVREE FOR WEIGHT MANAGEMENT IN ELIGIBLE ADULT AND PEDIATRIC PATIENTS AGED 6 YEARS AND OLDER WITH CLINICALLY OR GENETICALLY CONFIRMED BARDET-BIEDL SYNDROME (BBS) AND OBESITY. THESE LISTING AGREEMENTS FOR IMCIVREE MARK A SIGNIFICANT MILESTONE FOR INDIVIDUALS LIVING WITH OBESITY DUE TO BARDET-BIEDL SYNDROME, SAID PROF.

RHYTHM PHARMACEUTICALS ANNOUNCES PUBLIC REIMBURSEMENT FOR IMCIVREE (SETMELANOTIDE) IN CANADA IN FIVE PROVINCES AND UNDER THE FEDERAL NON-INSURED HEALTH BENEFITS PROGRAM

Rhythm Pharmaceuticals, Inc.

RYTM

Price

Financial Reports

No items found.

Press Releases

Rhythm Pharmaceuticals, Inc.

RYTM.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

RYTM